Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma | Nature Medicine

Neoadjuvant combination treatment with nivolumab and ipilimumab in patients with high-risk melanoma results in higher response rates than nivolumab monotherapy and warrants future optimization of dosing regimens to preserve efficacy while limiting toxicity.

saved by

• Pranav Bharadwaj